Anlon Healthcare Limited
NSE: AHCL · Pharmaceuticals · sector
₹24.70NSE close 2026-10-26
Key numbers
Market cap₹1,313 cr
Price₹24.70
52w high / low₹37 / ₹10
P/E33.9xSector median 27.9x
P/B5.7xSector median 2.9x
Book value₹4.3
Dividend yield–Sector median 0.48%
ROE14.4%Sector median 11.7%
ROCE20.1%Sector median 12.3%
OPM25.2%Sector median 14.0%
Debt / equity0.19xSector median 0.16x
EV/EBITDA23.7xSector median 18.6x
Interest cover14.0x
Current ratio2.87x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹4 cr vs borrowings ₹44 cr (FY26): borrowings are higher by ₹39 cr.
- Operating profit covered interest 14.0x in the last 12 months.
- Other income was 1% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹24.70 on 2026-10-26: -33.7% from the 52-week high, +138.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹32.86 · low ₹13.11
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 33 | 52 | 36 | 51 | 88 |
| EBITDA | 6 | 14 | 12 | 15 | 16 |
| OPM % | 18.7% | 26.3% | 34.7% | 30.0% | 17.8% |
| Other income | 0 | 0 | 0 | 0 | 0 |
| Net profit | 4 | 9 | 5 | 10 | 8 |
| EPS (₹) | 0.44 | 0.22 | 0.11 | 0.23 | 0.16 |
| Revenue YoY | +162.9% | ||||
| Profit YoY | +133.2% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 172 | 226 |
| EBITDA | 48 | 57 |
| Net profit | 29 | 33 |
| EPS (₹) | 0.61 | 0.73 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | +101.6% |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 230 |
| Borrowings | 44 |
| Cash & equivalents | 4 |
| Total assets | 374 |
| Fixed assets | 58 |
| Investments | 0 |
| Receivables | 104 |
| Inventory | 113 |
| Payables | 42 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | -79 |
| Cash from investing | -36 |
| Cash from financing | 119 |
| Capex | 0 |
| Free cash flow | -79 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 12.4% |
| ROCE % | 16.9% |
| Debtor days | 220 |
| Inventory days | 393 |
| Payable days | 147 |
| Cash conversion cycle (days) | 466 |
| Working capital days | 426 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 52.68% |
| FIIs | 1.00% |
| DIIs | 0.30% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.06% |
| Public (non-institutions) | 46.02% |
| Quarter | Sep 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Promoters % | 52.68% | 52.68% | 52.68% | 52.68% | 52.68% | 52.68% |
| Promoter group | % |
|---|---|
| Punitkumar R Rasadia | 34.98% |
| Meet Atulkumar Vachhani | 17.70% |
| Mamata Punitkumar Rasadia | 0.00% |
| Rasadia Bhanumati Rameshbhai | 0.00% |
| Shilpaben Meetbhai Vachhani | 0.00% |
| Rasadia Khush Punitkumar | 0.00% |
| Rameshbhai Maganbhai Ramotiya | 0.00% |
| Ramotiya Ramaben | 0.00% |
| Jayesh Rameshbhai Ramotiya | 0.00% |
| Sanjay Ramotiya R | 0.00% |
| Atulbhai Shyamlal Vachhani | 0.00% |
| Vachhani Bhartiben Atulbhai | 0.00% |
| Neha Nirmal Patel | 0.00% |
| Gyana Meetbhai Vachhani | 0.00% |
| Vari Meetbhai Vachhani | 0.00% |
| Public holders above 1% | % |
|---|---|
| Shree Dwarikadhish Ventures LLP | 7.53% |
| BAN Labs Private Limited | 5.27% |
| LUV Natwarlal Ukani | 1.13% |
| JAY Mauleshkumar Ukani | 1.13% |
| Harshad Rasiklal Sheth | 1.01% |
81,356 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| AHCL | ₹1,313 cr | 33.9x | 5.7x | 14.4% | 20.1% | 25.2% | – | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-04-24 | Split | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share |
| 2026-04-24 | Bonus | Bonus 1:1 |
Documents
- Annual report FY26
- Annual report FY26
- Annual report FY25
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | AHCL |
| BSE code | 544497 |
| ISIN | INE0Y8W01025 |
| Face value | ₹2.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.